Compare Comfort Systems USA Inc (FIX) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Comfort Systems USA Inc vs Merck & Co., Inc. — how do they compare? Comfort Systems USA Inc trades at $1,737.99 (market cap $61.29B), while Merck & Co., Inc. trades at $141.84 (market cap $352.29B). The key difference: Merck & Co., Inc. is far larger — about 5.7× Comfort Systems USA Inc's market cap, and Merck & Co., Inc. pays the higher dividend (2.38%). Which is the better fit depends on your goals — on Pluang, investors hold Comfort Systems USA Inc for 41 Days and Merck & Co., Inc. for 98 Days on average.
| FIX | MRK | |
|---|---|---|
Market Cap | $61.29B | $352.29B |
Volume | 365,637 | 6,348,796 |
Sector | Industrials | Health |
52-Week High | $2.07K | $156.43 |
52-Week Low | $790.72 | $82.49 |
Typical Hold Time | 41 Days | 98 Days |
Enterprise Value | $59.76B | $399.05B |
Dividend Yield | 0.21% | 2.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Comfort Systems USA (FIX) trades at $1,741.36, down 4.21% today but maintains strong technical momentum with bullish moving averages. The company demonstrates robust fundamentals with revenue growth from $9.1B in 2025 to $11.2B projected for 2026, supported by consistent earnings beats and a 55.29% ROE. Recent acquisition of Hunt Electric adds $250M in annual revenue, positioning FIX to capitalize on data center and infrastructure demand.
Outlook remains positive with analyst consensus at Buy (55.56%) and $2,080 price target representing 19% upside. Key risks include execution of growing project backlog and sensitivity to construction cycle fluctuations. The stock's premium valuation (P/E 42.86) requires sustained high growth to justify current levels amid competitive market conditions.
Merck (MRK) trades at $142.79, up 0.61% today, with a bearish technical signal but strong fundamental performance. The company reported revenue of $65.01B in 2025 with a net income margin of 28.07%, and recent quarterly EPS have consistently beaten expectations. Merck is actively expanding its pipeline through acquisitions, such as the pending $6.7B purchase of Terns Pharmaceuticals announced in April 2026.
The outlook is supported by solid profitability and analyst optimism, with a consensus price target of $158.78 implying upside. Key risks include integration challenges from acquisitions and competitive pressures in the oncology sector. Cash flow trends show variability, with a projected net cash outflow of $1.2B in 2026 due to significant investing activities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Comfort Systems USA Inc
Comfort Systems USA is a premier provider of mechanical and electrical contracting services. It specializes in HVAC, plumbing, and energy management solutions for commercial and industrial facilities.
Read more on FIX →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
